Literature DB >> 19036469

Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer.

Young Hak Kim1, Genichiro Ishii, Koichi Goto, Shuji Ota, Kaoru Kubota, Yukinori Murata, Michiaki Mishima, Nagahiro Saijo, Yutaka Nishiwaki, Atsushi Ochiai.   

Abstract

BACKGROUND: ATP-binding cassette (ABC) transporter and DNA excision repair proteins play a pivotal role in the mechanisms of drug resistance. The aim of this study was to investigate the expression of ABC transporter and DNA excision repair proteins, and to elucidate the clinical significance of their expression in biopsy specimens from patients with small-cell lung cancer (SCLC).
METHODS: We investigated expression of the ABC transporter proteins, P-glycoprotein (Pgp), multidrug resistance associated-protein 1 (MRP1), MRP2, MRP3, and breast cancer resistance protein (BCRP), and the DNA excision repair proteins, excision repair cross-complementation group 1 (ERCC1) protein and breast cancer susceptibility gene 1 (BRCA1) protein, in tumor biopsy specimens obtained before chemotherapy from 130 SCLC patients who later received platinum-based combination chemotherapy, and investigated the relationship between their expression and both response and survival.
RESULTS: No significant associations were found between expression of Pgp, MRP1, MRP2, MRP3, ERCC1, or BRCA1 and either response or survival. However, there was a significant association between BCRP expression and both response (p=0.026) and progression-free survival (PFS; p=0.0103).
CONCLUSIONS: BCRP expression was significantly predictive of both response and progression-free survival (PFS) in SCLC patients receiving chemotherapy. These findings suggest that BCRP may play a crucial role in drug resistance mechanisms, and that it may serve as an ideal molecular target for the treatment of SCLC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19036469     DOI: 10.1016/j.lungcan.2008.10.008

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  33 in total

Review 1.  The controversial role of ABC transporters in clinical oncology.

Authors:  Akina Tamaki; Caterina Ierano; Gergely Szakacs; Robert W Robey; Susan E Bates
Journal:  Essays Biochem       Date:  2011-09-07       Impact factor: 8.000

2.  Prognostic impact of membranous ATP-binding cassette Sub-family G member 2 expression in patients with colorectal carcinoma after surgical resection.

Authors:  Donghoon Kang; Jae Myung Park; Chan Kwon Jung; Bo-In Lee; Seong Taek Oh; Myung-Gyu Choi
Journal:  Cancer Biol Ther       Date:  2015-07-15       Impact factor: 4.742

Review 3.  Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.

Authors:  Karthika Natarajan; Yi Xie; Maria R Baer; Douglas D Ross
Journal:  Biochem Pharmacol       Date:  2012-01-11       Impact factor: 5.858

4.  Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study.

Authors:  Chunqiao Tian; Christine B Ambrosone; Kathleen M Darcy; Thomas C Krivak; Deborah K Armstrong; Michael A Bookman; Warren Davis; Hua Zhao; Kirsten Moysich; Holly Gallion; Julie A DeLoia
Journal:  Gynecol Oncol       Date:  2011-11-21       Impact factor: 5.482

5.  Human ABCG2: structure, function, and its role in multidrug resistance.

Authors:  Wei Mo; Jian-Ting Zhang
Journal:  Int J Biochem Mol Biol       Date:  2011-03-30

Review 6.  The challenge of exploiting ABCG2 in the clinic.

Authors:  Robert W Robey; Caterina Ierano; Zhirong Zhan; Susan E Bates
Journal:  Curr Pharm Biotechnol       Date:  2011-04       Impact factor: 2.837

Review 7.  Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies.

Authors:  Laleh Amiri-Kordestani; Agnes Basseville; Karen Kurdziel; Antonio Tito Fojo; Susan E Bates
Journal:  Drug Resist Updat       Date:  2012-03-29       Impact factor: 18.500

8.  ABCG2 expression in colorectal adenocarcinomas may predict resistance to irinotecan.

Authors:  Hoang Dinh Tuy; Hisanori Shiomi; Ken Ichi Mukaisho; Shigeyuki Naka; Tomoharu Shimizu; Hiromichi Sonoda; Eiji Mekata; Yoshihiro Endo; Yoshimasa Kurumi; Hiroyuki Sugihara; Masaji Tani; Tohru Tani
Journal:  Oncol Lett       Date:  2016-08-03       Impact factor: 2.967

9.  A polymorphism at the miR-502 binding site in the 3' untranslated region of the SET8 gene is associated with the outcome of small-cell lung cancer.

Authors:  Cuimin Ding; Ruijuan Li; Jingcui Peng; Shengmian Li; Zhanjun Guo
Journal:  Exp Ther Med       Date:  2012-02-03       Impact factor: 2.447

10.  Individualized Chemotherapy in Advanced NSCLC Patients Based on mRNA Levels of BRCA1 and RRM1.

Authors:  Sheng-Xiang Ren; Ai-Wu Li; Song-Wen Zhou; Ling Zhang; Yong-Sheng Wang; Bing Li; Xiao-Xia Chen; Jie Zhang; Jian-Fang Xu; Cai-Cun Zhou
Journal:  Chin J Cancer Res       Date:  2012-09       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.